Previous Article | Next Article ![]()
J. Virol., Jan 1998, 279-285, Vol 72, No. 1
T Dragic, A Trkola, SW Lin, KA Nagashima, F Kajumo, L Zhao, WC Olson, L Wu, CR Mackay, GP Allaway, TP Sakmar, JP Moore and PJ Maddon
The CC-chemokine receptor CCR5 is required for the efficient fusion of
macrophage (M)-tropic human immunodeficiency virus type 1 (HIV-1) strains
with the plasma membrane of CD4+ cells and interacts directly with the
viral surface glycoprotein gp120. Although receptor chimera studies have
provided useful information, the domains of CCR5 that function for HIV-1
entry, including the site of gp120 interaction, have not been unambiguously
identified. Here, we use site-directed, alanine- scanning mutagenesis of
CCR5 to show that substitutions of the negatively charged aspartic acid
residues at positions 2 and 11 (D2A and D11A) and a glutamic acid residue
at position 18 (E18A), individually or in combination, impair or abolish
CCR5-mediated HIV-1 entry for the ADA and JR-FL M-tropic strains and the
DH123 dual-tropic strain. These mutations also impair Env-mediated membrane
fusion and the gp120-CCR5 interaction. Of these three residues, only D11 is
necessary for CC-chemokine-mediated inhibition of HIV-1 entry, which is,
however, also dependent on other extracellular CCR5 residues. Thus, the
gp120 and CC-chemokine binding sites on CCR5 are only partially
overlapping, and the former site requires negatively charged residues in
the amino-terminal CCR5 domain.
Copyright © 1998, American Society for Microbiology
Amino-terminal substitutions in the CCR5 coreceptor impair gp120 binding and human immunodeficiency virus type 1 entry
Aaron Diamond AIDS Research Center, The Rockefeller University, New York, New York 10016, USA. tdragic@adarc.org
This article has been cited by other articles:
| J. Bacteriol. | Mol. Cell. Biol. | Microbiol. Mol. Biol. Rev. |
|---|
| Clin. Vaccine Immunol. | ALL ASM JOURNALS |
|---|